Genedx Holdings Corp. (filing registrant: Sema4 Holdings Corp.) — Q2 2022 Form 10-Q
Business context and reporting period. This unaudited quarterly report covers the three and six months ended June 30, 2022. The filing is by Sema4 Holdings Corp. (Nasdaq: SMFR, warrants: SMFRW), not an entity named GeneDx Holdings Corp. Sema4 acquired GeneDx on April 29, 2022; reported results include GeneDx only from the acquisition date. The combined company provides genomic diagnostic testing and related data services.
Financial results and liquidity
| Metric | Q2 2022 | Q2 2021 | First half 2022 | First half 2021 |
|---|---|---|---|---|
| Revenue | $36.2 million | $47.0 million | $90.1 million | $111.2 million |
| Gross profit (loss) | $(29.6) million | $(1.2) million | $(24.0) million | $(5.5) million |
| Gross margin | (82)% | (2)% | (27)% | (5)% |
| Operating loss | $(162.6) million | $(45.4) million | $(252.0) million | $(242.1) million |
| Net loss | $(85.7) million | $(46.2) million | $(162.6) million | $(237.9) million |
| Operating cash flow | Not provided for quarter | Not provided for quarter | $(166.1) million | $(67.5) million |
- Q2 diagnostic revenue was $34.0 million, down 24%; other revenue was $2.2 million. The filing attributes the diagnostic revenue decline chiefly to a $30.1 million estimate reduction for prior-period tests, including $24.2 million relating to 2021 and earlier. GeneDx contributed $26.1 million of revenue and $9.0 million of pretax loss in the post-acquisition period.
- For the first half, non-GAAP adjusted EBITDA was a loss of $173.9 million, versus a loss of $62.0 million a year earlier. Q2 adjusted EBITDA loss was $115.0 million versus $37.2 million. These are company-defined non-GAAP measures.
- At June 30, cash and cash equivalents were $284.6 million; restricted cash was $14.4 million, including $13.5 million held in acquisition escrow. Total cash, cash equivalents and restricted cash were $299.0 million, down from $401.5 million at year-end 2021.
- Debt was $11.0 million. The company had not drawn on its $125 million revolving credit facility. Lease liabilities totaled $68.4 million. Management stated available cash and the facility were expected to fund operations for at least 12 months from the filing date.
- Current assets were $402.7 million and current liabilities $204.6 million. Accounts payable and accrued expenses included $39.2 million of reserves for insurance-payor refunds.
Material changes and transactions
- The GeneDx acquisition was funded with $150 million gross cash consideration and 80 million Sema4 shares valued at $172 million at closing. A separate $200 million private placement generated approximately $197.7 million net proceeds. Up to $150 million more may be payable to OPKO through revenue-based milestones; the recorded fair value was $35 million at June 30, of which $28 million was classified as current.
- Q2 operating expenses rose substantially year over year, including general and administrative expense of $68.0 million versus $12.9 million, reflecting acquisition, integration, personnel, stock compensation and other costs. Q2 included $9.1 million of transaction, acquisition and integration costs and $6.8 million of restructuring costs in the company’s adjusted EBITDA reconciliation.
- Cash used in investing activities was $134.2 million in the first half, primarily reflecting $127.0 million of net cash paid for GeneDx, plus equipment and software spending. Financing activities provided $197.9 million, principally from the acquisition PIPE.
- The company reported 379.9 million common shares outstanding at June 30 and 380.6 million at August 9. OPKO received 80 million shares, with 8.3 million shares held in escrow for one year. Potential milestone shares, warrants, options and other awards may add dilution.
Outlook, risks and unusual items
- After quarter-end, on August 11, the board approved exiting somatic tumor testing and closing the Branford laboratory by December 31, 2022. Management said the business represented less than 1% of revenue and approximately $35 million of annual expenses, and expected cost savings and improved gross margins. The company estimated $8.5–$11.5 million in cash charges, primarily severance, mainly in the second half of 2022; additional non-cash charges were not yet estimable.
- The same plan eliminates approximately 250 positions, about 13% of the workforce; combined with earlier 2022 reductions, the company said this would eliminate about 30% of Legacy Sema4 roles. COVID-19 testing had already been discontinued as of March 31, 2022.
- Management cited reimbursement and payor recoupment uncertainty as a significant risk. One payor alleged overpayments and threatened recovery; Sema4 said it believed it had defenses and was seeking resolution. The $39.2 million reserve reflects this matter and other potential settlements, and may change as information develops.
- Reported net loss benefited from a $49.1 million income-tax benefit following a valuation-allowance release associated with deferred tax liabilities recorded in the GeneDx acquisition. A $41.4 million first-half gain from remeasurement of warrant and earn-out liabilities also reduced reported losses; these are non-cash and can fluctuate with fair values.
- Disclosure controls were deemed ineffective at June 30 because previously identified material weaknesses in financial reporting controls had not been fully remediated. Management nevertheless stated the interim financial statements were fairly stated in all material respects.
- After quarter-end, President and Chief Research & Development Officer Eric Schadt agreed to depart, with 24 months of salary and COBRA reimbursement under a separation agreement. CEO Katherine Stueland was appointed President effective August 15; other senior departures and a new Chief Technology and Product Officer were also disclosed.
- Key risks include further reimbursement reductions or recoupments, integration and execution of the GeneDx acquisition, ongoing losses and cash burn, ability to raise capital, regulatory and laboratory compliance, data privacy and cybersecurity, supplier concentration, and Nasdaq listing compliance. The filing provides no numerical revenue or profitability guidance.
Important facts for investors to verify
- Confirm the correct issuer and security: this filing is Sema4 Holdings Corp.’s 10-Q, although the request identifies GeneDx Holdings Corp.
- Track the outcome and any further reserve changes related to the payor dispute and the $39.2 million refund reserve, including effects on reimbursement rates.
- Assess GeneDx’s progress toward the 2022 revenue milestone of $163 million and 2023 target of $219 million, which determine potential payments of up to $150 million.
- Monitor cash burn, liquidity and financing needs against management’s stated 12-month runway, including the facility’s conditions and the planned restructuring costs.
- Verify actual savings, charges and operational effects from the tumor-testing exit, laboratory closure and workforce reductions.
- Follow remediation of material weaknesses and any subsequent changes in disclosure-control effectiveness, as well as dilution from OPKO shares, milestone consideration and outstanding equity awards.